<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03351361</url>
  </required_header>
  <id_info>
    <org_study_id>2017-002842-60</org_study_id>
    <secondary_id>35RC16_9734</secondary_id>
    <secondary_id>08-2015</secondary_id>
    <secondary_id>CA209-449</secondary_id>
    <nct_id>NCT03351361</nct_id>
  </id_info>
  <brief_title>Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients</brief_title>
  <acronym>eNERGY</acronym>
  <official_title>Randomized Phase III Study Testing Nivolumab and Ipilimumab Versus a Carboplatin Based Doublet in First Line Treatment of PS 2 or Elderly (More Than 70 Years Old) Patients With Advanced Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lung cancer is the most common cancer in the world and the leading cause of cancer-related&#xD;
      deaths in Western countries. Unfortunately, at the time of diagnosis, the majority of&#xD;
      patients already have metastatic disease and a systemic, palliative treatment is the primary&#xD;
      therapeutic option.&#xD;
&#xD;
      Guidelines for PS 2 patients or older than 75 years old patients at the time of diagnosis&#xD;
      recommend for fit patients a carboplatin doublet chemotherapy.&#xD;
&#xD;
      Nivolumab has proven efficacy in 3rd line squamous cell lung carcinoma and is superior to&#xD;
      chemotherapy in 2nd line treatment of squamous and non-squamous lung cancer in term of&#xD;
      overall survival.&#xD;
&#xD;
      In 1st line, nivolumab failed to show superiority compared to a platin based doublet in terms&#xD;
      of progression free survival and overall survival in tumors ≥ 5% PD-L1 expression. The&#xD;
      association Nivolumab plus Ipilimumab showed encouraging results in first line setting in&#xD;
      phase 1 study.&#xD;
&#xD;
      The investigators think that with regard to the manageable toxicity of nivolumab in lung&#xD;
      cancer population and the possibility to obtain long responses, this association could be a&#xD;
      valid option for this population of elderly and/or PS2 patients in term of overall survival.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 19, 2018</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Actual">July 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of randomization until the date of date of death from any cause, whichever came first, assessed up to 3 years maximum</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>2 years</time_frame>
    <description>according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years maximum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety rate</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events according to CTCAE version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability rate</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events according to CTCAE version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years maximum</time_frame>
    <description>according to EQ-5D questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years maximum</time_frame>
    <description>according to EORTC QLQ-ELD14 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD-L1</measure>
    <time_frame>2 years</time_frame>
    <description>testing by immunochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geriatric evaluation</measure>
    <time_frame>inclusion and 2 months</time_frame>
    <description>according to geriatric mini data set</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">217</enrollment>
  <condition>Advanced Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>carboplatin and pemetrexed or carboplatin and paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab + Ipilimumab</intervention_name>
    <description>Nivolumab dosed intravenously over 30 minutes at 240 mg every 2 weeks combined with Ipilimumab dosed intravenously over 30 minutes at 1 mg/kg every 6 weeks until disease progression, unacceptable toxicity, or other reasons specified in the protocol.</description>
    <arm_group_label>Nivolumab + Ipilimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Doublet of chemotherapy according to standard of care carboplatin (AUC 5) with a dose that will be capped to 700 mg and pemetrexed (500 mg/m²) over 4 to 6 hours every three weeks (restricted to non-squamous histology) or carboplatin (AUC 6) with a dose that will be capped to 700 mg and paclitaxel (90 mg/m²) D1 D8 D15 over 4 to 6 hours every 4 weeks, with a maximum of 4 cycles of carboplatin based doublet, and the possibility to use maintenance with pemetrexed.</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  Cytologically or histologically proven NSCLC (adenocarcinoma, squamous cell carcinoma,&#xD;
             large-cell carcinoma)&#xD;
&#xD;
          -  Stage IV or non-treatable by radiotherapy or surgery stage III (7th classification)&#xD;
&#xD;
          -  No previous systemic chemotherapy for lung cancer, except in case of relapse after&#xD;
             adjuvant treatment for localized disease with 6 months or more between end of previous&#xD;
             chemotherapy and relapse&#xD;
&#xD;
          -  Patients less than 70 years old and PS 2 or 70 years older PS 0 to 2&#xD;
&#xD;
          -  Judged fit enough to receive a carboplatin based doublet according to ESMO guidelines&#xD;
&#xD;
          -  Presence of at least one measurable target lesion (RECIST 1.1 rules) in a&#xD;
             non-irradiated region and analysable by CT&#xD;
&#xD;
          -  Life expectancy superior at 12 weeks&#xD;
&#xD;
          -  Prior radiation therapy is authorized if it involved less than 25% of the total bone&#xD;
             marrow volume and finished 14 days before D1 of planned treatment&#xD;
&#xD;
          -  Screening laboratory values must meet the following criteria and should be obtained&#xD;
             within 14 days prior to randomization/registration WBC superior or equal at at 2000/μL&#xD;
             Neutrophils superior or equal at at 1500/μL Platelets superior or equal at at 100&#xD;
             x103/μL Hemoglobin superior at 10.0 g/dL Serum creatinine inferior or equal at 1.5 x&#xD;
             ULN or creatinine clearance (CrCl) superior or equal at at 45 mL/min (if using the&#xD;
             Cockcroft-Gault formula ) AST/ALT inferior or equal at 3 x ULN Total Bilirubin&#xD;
             inferior or equal at 1.5 x ULN (except Patients with Gilbert Syndrome, who can have&#xD;
             total bilirubin inferior at 3.0 mg/dL)&#xD;
&#xD;
          -  Availability of adequate FFPE tumor-derived material (tumor blocks or slides) from a&#xD;
             biopsy, surgery or fine needle aspirate for analysis of PD-L1 testing by IHC&#xD;
&#xD;
        Age and Reproductive Status&#xD;
&#xD;
        • Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception&#xD;
        during treatment.&#xD;
&#xD;
        WOCBP should use an adequate method to avoid pregnancy :&#xD;
&#xD;
          -  For 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives)&#xD;
             after the last dose of nivolumab + ipilimumab,&#xD;
&#xD;
          -  For 4 weeks after the last dose of carboplatine + pemetrexed,&#xD;
&#xD;
          -  For 5 weeks after the last dose of carboplatine + paclitaxel.&#xD;
&#xD;
               -  Women of childbearing potential must have a negative serum or urine pregnancy&#xD;
                  test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours&#xD;
                  prior to the start of treatment&#xD;
&#xD;
               -  Women must not be breastfeeding&#xD;
&#xD;
               -  Men who are sexually active with WOCBP must use any contraceptive method with a&#xD;
                  failure rate of less than 1% per year during treatment Men will be instructed to&#xD;
                  adhere to contraception for a period of 31 weeks after the last dose of nivolumab&#xD;
                  + ipilimumab and with carboplatine +pemetrexed or carboplatine + paclitaxel up to&#xD;
                  6 months thereafter.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with other severe concurrent disorders that occurred during the prior six&#xD;
             months before enrollment (myocardial infection, severe or unstable angor, coronarian&#xD;
             or peripheric arterial bypass operation, NYHA class 3 or 4 congestive heart failure,&#xD;
             transient or constituted cerebral ischemic attack, at least grade 2 peripheral&#xD;
             neuropathy, psychiatric or neurological disorders preventing the patient from&#xD;
             understanding the trial, uncontrolled infections) are not eligible.&#xD;
&#xD;
          -  Serious or uncontrolled systemic disease judged as incompatible with the protocol by&#xD;
             the investigator&#xD;
&#xD;
          -  Another previous or concomitant cancer, except for basocellular cancer of the skin or&#xD;
             treated cervical cancer in situ, or appropriately treated localized low-grade prostate&#xD;
             cancer (Gleason score inferior at 6), unless the initial tumor was diagnosed and&#xD;
             definitively treated more than 5 years previously, with no evidence of relapse.&#xD;
&#xD;
          -  Known activating mutation of EGFR (del LREA exon 19, mutation L858R or L861X of exon&#xD;
             21, mutation G719A/S in exon 18) or EML4-ALK or ROS-1 translocation&#xD;
&#xD;
          -  Superior at caval syndrome&#xD;
&#xD;
          -  Uncontrolled infectious status&#xD;
&#xD;
          -  All concurrent radiotherapy&#xD;
&#xD;
          -  Concurrent administration of one or several other anti-tumor therapies.&#xD;
&#xD;
          -  Psychological, familial, social or geographic difficulties preventing follow-up as&#xD;
             defined by the protocol.&#xD;
&#xD;
          -  Protected person (adults legally protected (under judicial protection, guardianship or&#xD;
             supervision), person deprived of their liberty, pregnant woman, lactating woman and&#xD;
             minor),&#xD;
&#xD;
          -  Concurrent participation in another clinical trial&#xD;
&#xD;
          -  Patients are excluded if they have active brain metastases or leptomeningeal&#xD;
             metastases. Patients with brain metastases are eligible if metastases have been&#xD;
             treated and there is no magnetic resonance imaging (MRI) evidence of progression for&#xD;
             [lowest minimum is 4 weeks or more] after treatment is complete and within 28 days&#xD;
             prior to the first dose of nivolumab and ipilimumab administration. There must also be&#xD;
             no requirement for immunosuppressive doses of systemic corticosteroids (superior at 10&#xD;
             mg/day prednisone equivalents) for at least 2 weeks prior to study drug&#xD;
             administration.&#xD;
&#xD;
          -  Patients should be excluded if they have an active, known or suspected autoimmune&#xD;
             disease. Patients are permitted to enroll if they have vitiligo, type I diabetes&#xD;
             mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone&#xD;
             replacement, psoriasis not requiring systemic treatment, or conditions not expected to&#xD;
             recur in the absence of an external trigger&#xD;
&#xD;
          -  Patients should be excluded if they have a condition requiring systemic treatment with&#xD;
             either corticosteroids (superior at 10 mg daily prednisone equivalents) or other&#xD;
             immunosuppressive medications within 14 days of study drug administration. Inhaled or&#xD;
             topical steroids and adrenal replacement doses superior at 10 mg daily prednisone&#xD;
             equivalents are permitted in the absence of active autoimmune disease.&#xD;
&#xD;
          -  Patients should be excluded if they are positive test for hepatitis B virus surface&#xD;
             antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating&#xD;
             acute or chronic infection&#xD;
&#xD;
          -  Patients should be excluded if they have known history of testing positive for human&#xD;
             immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)&#xD;
&#xD;
          -  Patients should be excluded if they have a lung disease that is symptomatic or may&#xD;
             interfere with the detection or management of suspected drug-related pulmonary&#xD;
             toxicity&#xD;
&#xD;
          -  Allergies and Adverse Drug Reaction&#xD;
&#xD;
          -  History of allergy to study drug components&#xD;
&#xD;
          -  Severe spinal hypoplasia and / or hemorrhagic tumors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hervé Léna</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH du Pays d'Aix</name>
      <address>
        <city>Aix-en-Provence</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Beauvais</name>
      <address>
        <city>Beauvais</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH René Dubos</name>
      <address>
        <city>Cergy-Pontoise</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Charleville-Mézières</name>
      <address>
        <city>Charleville-Mézières</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HIA Percy</name>
      <address>
        <city>Clamart</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Intercommunal</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Elbeuf</name>
      <address>
        <city>Elbeuf</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Intercommunal des Alpes du Sud</name>
      <address>
        <city>Gap</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Départemental Vendée</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Versailles</name>
      <address>
        <city>Le Chesnay</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Robert Boulin</name>
      <address>
        <city>Libourne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Bretagne Sud</name>
      <address>
        <city>Lorient</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH François Quesnay</name>
      <address>
        <city>Mantes-la-Jolie</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHM Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmette</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Meaux</name>
      <address>
        <city>Meaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de la Région d'Annecy</name>
      <address>
        <city>Pringy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Quimper</name>
      <address>
        <city>Quimper</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Saint-Brieuc</name>
      <address>
        <city>Saint-Brieuc</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Saint-Nazaire</name>
      <address>
        <city>Saint-Nazaire</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Saint-Etienne</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CLCC Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Suresnes</name>
      <address>
        <city>Suresnes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Intercommunal Toulon-La Seyne-sur-Mer</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HIA Saint-Anne</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Villefranche sur Saône</name>
      <address>
        <city>Villefranche-sur-Saône</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Villeneuve-Saint-Georges</name>
      <address>
        <city>Villeneuve-Saint-Georges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>November 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2017</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 6, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03351361/Prot_SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 6, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03351361/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

